JUST IN: $IMMU Should You Buy Gilead Now That It's Acquiring Immunomedics?
Many investors have long hoped that Gilead Sciences (NASDAQ: GILD) would use its massive cash stockpile to fund a major acquisition. That hope is now being fulfilled. Gilead announced on Sunday that it plans to acquire Immunomedics (NASDAQ: IMMU) for around $21 billion. At nearly...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.